Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 7/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.52 |
| ▸ | MME | P08473 | 10/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 9/20 | 0.50 |
| ▸ | ACE | P12821 | 8/20 | 0.50 |
| ▸ | CPA1 | P15085 | 7/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7102714 | 0.80 | PPARG (0.53) | ITGB1ITGA4APPPPARGPPARA | |
| SCHEMBL7102711 | 0.80 | PPARG (0.53) | ITGB1ITGA4APPPPARGPPARA | |
| SCHEMBL7258050 | 0.79 | ITGB1 (0.43) | ITGB1ITGA4 | |
| SCHEMBL7258056 | 0.79 | ITGB1 (0.43) | ITGB1ITGA4 | |
| SCHEMBL7715716 | 0.77 | ITGB1 (0.43) | ITGB1ITGA4MMEACE2ACE | |
| SCHEMBL7259939 | 0.77 | ITGB1 (0.47) | ITGB1ITGA4 | |
| SCHEMBL7716188 | 0.77 | ITGB1 (0.43) | ITGB1ITGA4 | |
| SCHEMBL7259945 | 0.77 | ITGB1 (0.47) | ITGB1ITGA4 | |
| SCHEMBL7264612 | 0.77 | ITGB1 (0.79) | ITGB1ITGA4 | |
| SCHEMBL7714207 | 0.77 | ITGB1 (0.42) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455539-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIPROLIFERATORY AGENTS | CELLTECH R&D LIMITED (GB) | 2002-09-24 | — | — | US | disclosed |
| US-20010020017-A1 | Squaric acid derivatives | CELLTECH R&D LIMITED (GB) | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020017-A1 | Squaric acid derivatives | SUCNR1, HCAR1, CCR1 | ITGB1 20/4885ITGA4 435/4885MME 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.